A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Fibromyalgia
- Focus Registrational; Therapeutic Use
- Acronyms AFFIRM
- Sponsors Tonix Pharmaceuticals Inc
- 23 Sep 2016 Status changed from active, no longer recruiting to completed.
- 06 Sep 2016 Top-line results published in a Tonix Pharmaceuticals Holding Corp media release.
- 06 Sep 2016 Primary endpoint (Average perceived pain) has not been met, according to a Tonix Pharmaceuticals Holding Corp media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History